This study was done to determine whether providing intravenous alanyl-glutamine (0.5 g/kg/day)will be associated with improved clinical outcomes in the term of reduced severity of organ dysfunction, length of stay in ICU, length of stay in hospital, number of days on mechanical ventilation, number of days of antibiotic use during ICU stay, in hospital mortality in compared with placebo in critically ill burn patient.